Cellular Dynamics International

Cellular Dynamics International (CDI) was a United States biotechnology company focused on turning induced pluripotent stem-cell technology into standardized human-cell products and research services. Founded in 2004 and associated with stem-cell pioneer James Thomson, the company sought to provide pharmaceutical companies, biotechnology firms, and academic researchers with human cells that could be used in place of less predictive experimental models, including animal cells, immortalized cell lines, and cadaver-derived material. CDI's commercial portfolio was built around the iCell and MyCell product families. iCell products were catalog cells differentiated from pluripotent stem cells into specialized human cell types, including cardiomyocytes, neurons, endothelial cells, and hepatocytes. These products were designed for applications such as high-throughput screening, electrophysiology, disease modeling, toxicity studies, and support for drug-development programs. MyCell products used customer-provided donor samples and CDI's reprogramming, gene-editing, and differentiation capabilities to create cells reflecting particular genetic backgrounds, disease states, or phenotypes. Cardiac biology was an early center of gravity for the company. Its iCell Cardiomyocytes were used to study cardiac function, drug effects, and potential cardiotoxicity, while later cardiac progenitor products supported heart-failure and regenerative-medicine research. CDI expanded into neural, hepatic, vascular, and blood-cell applications, with products and prototypes including neurons, dopaminergic neurons, astrocytes, hepatocytes, endothelial cells, hematopoietic progenitors, and skeletal myoblasts. The company also pursued cell banking and large-scale reprogramming programs intended to make induced pluripotent stem-cell resources available across diverse human populations and disease groups. CDI became a publicly traded company in 2013 through an initial public offering under the ticker ICEL. Its technology portfolio reportedly included more than 800 patents and licensed technologies by that period. In the same year, the California Institute for Regenerative Medicine awarded the company a major contract to reprogram and bank induced pluripotent stem cells from 3,000 individuals. CDI also participated in a National Heart, Lung, and Blood Institute-supported project with the Medical College of Wisconsin involving donor-derived cell lines and cardiomyocytes for research into left-ventricular hypertrophy. On March 30, 2015, Fujifilm Holdings Corporation announced an agreement to acquire CDI for $307 million, equivalent to $16.50 per share on a fully diluted basis. Following completion of the transaction, the company was renamed Fujifilm Cellular Dynamics, Inc. The independent CDI corporate brand therefore became defunct, although its cell-production technologies, products, and research activities continued within Fujifilm's life-sciences operations. CDI received recognition from technology and scientific publications, including appearances on MIT Technology Review's disruptive-company lists and awards for its iCell Cardiomyocyte and MyCell platforms.

Cellular Dynamics International was established in 2004 to commercialize technologies for producing human cells from induced pluripotent stem cells. The company's work was connected to the maturation of iPSC research from an academic technique into a platform for scalable disease modeling, drug screening, and regenerative-medicine research. Rather than offering only research reagents or pursuing a single therapeutic candidate, CDI developed differentiated human cells intended to be supplied in consistent formats to laboratories and pharmaceutical researchers. The company initially developed a strong position in cardiac-cell applications. Its iCell Cardiomyocytes were designed to reproduce important functional characteristics of human heart muscle cells and became a tool for pharmacology, electrophysiology, safety testing, and toxicity research. CDI subsequently expanded its portfolio into neural, hepatic, vascular, and blood-cell products. The broader iCell range included neurons, endothelial cells, and hepatocytes, while prototype and developmental products included cardiac progenitors, hematopoietic progenitors, astrocytes, and skeletal myoblasts. CDI also developed the MyCell platform for customer-specific work. Under this model, donor samples could be reprogrammed into iPSCs, subjected to genetic engineering or gene editing, and differentiated into relevant cell types. This approach supported disease modeling using cells that retained donor-specific genetic characteristics and offered potential uses in screening, mechanism-of-disease research, and regenerative medicine. The company's products were used or studied in areas including Parkinson's disease, autism, Alzheimer's disease, virology, hepatotoxicity, vascular biology, autoimmune disease, cancer, and cardiac disease. Cell banking became another strategic area. CDI participated in projects intended to create collections of iPSC lines representing different disease states, genetic backgrounds, and drug-response profiles. In 2013, the California Institute for Regenerative Medicine awarded CDI a $16 million contract to reprogram and bank cells from 3,000 individuals. The resulting biorepository was managed by CDI and housed at Fujifilm Irvine Scientific. CDI also worked with the Medical College of Wisconsin on a National Heart, Lung, and Blood Institute-supported project involving iPSC lines and cardiomyocytes derived from selected participants in the HyperGEN study. By 2013, CDI had entered the public markets under the ticker ICEL and reported a technology portfolio of more than 800 patents and licensed technologies. Its products and platform received recognition from technology and scientific publications, including MIT Technology Review, The Scientist, and The Wall Street Journal. The company was listed among MIT Technology Review's disruptive companies in 2011 and 2012, while iCell Cardiomyocytes and the MyCell platform received innovation recognition. On March 30, 2015, Fujifilm Holdings Corporation announced an agreement to purchase CDI for $307 million, or $16.50 per share on a fully diluted basis. After the acquisition, the company changed its name to Fujifilm Cellular Dynamics, Inc. The standalone CDI brand and public-company identity consequently ended, while the underlying cell-manufacturing business continued as part of Fujifilm's life-sciences organization.

1. 2015Acquisition by Fujifilm

   Fujifilm announced an agreement to acquire CDI for $307 million, after which the company was renamed Fujifilm Cellular Dynamics.

   Source
2. 2013Initial public offering

   CDI completed an initial public offering and traded under the symbol ICEL.

   Source
3. 2013Large-scale CIRM cell-banking contract

   The California Institute for Regenerative Medicine awarded CDI a $16 million contract involving iPSC reprogramming and banking for 3,000 individuals.

   Source
4. 2012Further technology recognition

   CDI again appeared on MIT Technology Review's disruptive-companies list, while its MyCell platform was recognized by The Scientist.

   Source
5. 2011CDI recognized as a disruptive company

   CDI appeared on MIT Technology Review's disruptive-companies list and its iCell Cardiomyocyte product received a Wall Street Journal technology innovation award.

   Source
6. 2010iCell Cardiomyocytes receive innovation recognition

   The company's iCell Cardiomyocyte product was recognized by The Scientist and included among MIT Technology Review's emerging technologies.

   Source
7. 2004Company founded

   Cellular Dynamics International was established to commercialize induced-pluripotent-stem-cell technology and manufacture differentiated human cells.

   Source

A commercial stem-cell technology specialist providing standardized and customized human cellular models for pharmaceutical research, disease modeling, toxicity assessment, and regenerative-medicine development.

• iCell CardiomyocytesCardiac cell product

  Human cardiomyocytes differentiated from induced pluripotent stem cells for cardiac biology, electrophysiology, pharmaceutical screening, drug-safety assessment, toxicology, and support of drug-development submissions. The product was CDI's best-known early commercial offering.

• iCell NeuronsNeural cell product

  Induced-pluripotent-stem-cell-derived neurons used in research involving neurodegenerative disease, neurotoxicity, autism, Alzheimer's disease, Parkinson's disease, and virology. The neural portfolio was later expanded with dopaminergic neurons and astrocytes.

• iCell HepatocytesHepatic cell product

  Human liver cells intended to support drug-metabolism research and earlier assessment of hepatotoxicity. The product addressed the need for more predictive human cellular models during pharmaceutical discovery and development.

• iCell Endothelial CellsVascular cell product

  Induced-pluripotent-stem-cell-derived endothelial cells used to model vascular biology and investigate the contribution of blood-vessel function to disease. They supported research in screening, vascular mechanisms, and regenerative medicine.

• MyCell ProductsCustom donor-derived cell platform

  A customized service and product family using customer-provided donor samples. CDI could reprogram the samples, apply genetic engineering or gene editing, and differentiate the resulting cells into relevant human cell types for disease modeling and personalized research.

• iCell Cardiac ProgenitorsCardiac progenitor cell product2014

  Progenitor cells designed for cardiac-development and heart-failure research, including studies related to regenerative medicine and the generation of specialized cardiac cell populations.

• iCell Hematopoietic ProgenitorsBlood progenitor cell product

  Multipotent blood-cell progenitors intended for research into blood-cell development, cell therapy, autoimmune disease, and cancer biology.

• iCell AstrocytesNeural cell product

  Stem-cell-derived astrocytes developed for studies of neural support cells, neurodegenerative disease, toxicity, and interactions between astrocytes and neurons.

• 2015Accept acquisition by FujifilmM&A

  Fujifilm sought to expand its life-sciences capabilities through CDI's induced-pluripotent-stem-cell manufacturing and human-cell product platform.

  What changed. Fujifilm Holdings agreed to acquire CDI for $307 million, equivalent to $16.50 per share on a fully diluted basis.

  Aftermath. The standalone CDI company was renamed Fujifilm Cellular Dynamics, Inc., ending CDI's independent corporate and public-market identity.

  Acquisition value. $307,000,000 (Announced March 30, 2015)

  Source
• 2013Scale induced-pluripotent-stem-cell bankingStrategy

  CDI pursued large population-scale cell resources to improve the representation of human genetic diversity, disease states, and adverse drug responses in laboratory research.

  What changed. The company accepted a California Institute for Regenerative Medicine contract to reprogram and bank iPS cells from 3,000 individuals and managed the resulting biorepository.

  Aftermath. The program strengthened CDI's role in cell banking and large-scale stem-cell infrastructure.

  Contract value. $16,000,000 (2013)

  Source

• 2015Fujifilm announces agreement to acquire Cellular Dynamics International

  Fujifilm Holdings announced an agreement to acquire CDI for $307 million, or $16.50 per share on a fully diluted basis. CDI was subsequently renamed Fujifilm Cellular Dynamics.

  M&A
  Source
• 2013Cellular Dynamics International completes initial public offering

  CDI became a publicly traded biotechnology company under the ticker ICEL, providing capital for the development and commercialization of induced-pluripotent-stem-cell-derived products.

  Other
  Source
• 2013California Institute for Regenerative Medicine awards CDI a major cell-banking contract

  CDI received a contract to reprogram and bank induced pluripotent stem cells from 3,000 individuals, supporting a large-scale resource for research into human diversity, disease, and drug response.

  Other
  Source

1. Cellular Dynamics International